# Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)

> **NCT01470690** · PHASE1 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 24 (actual)

## Conditions studied

- HCV Infections
- Gastric Acid-related Disorders

## Interventions

- **DRUG:** boceprevir
- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT01470690
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2011-12
- **Final completion:** 2012-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-12-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01470690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01470690, "Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01470690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*